Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Le Kremlin-Bicetre – page 21

297 clinical trials in Le Kremlin-Bicetre, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Le Kremlin-Bicetre at a glance
297
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

297 trials in Le Kremlin-Bicetre

Open in trial search

Sjogren's syndrome

Not recruiting

Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren's Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leflunomide
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Inhaled Imatinib (AV-101) for Patients with Pulmonary Arterial Hypertension (PAH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Novartis Pharma AG

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

Not recruiting

Study on the Effects and Safety of INZ-701 for Children with ENPP1 Deficiency

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Lupus nephritis+1

Not recruiting

Study of Ravulizumab for Adults with Lupus Nephritis or IgA Nephropathy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Pulmonary arterial hypertension

Not recruiting

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALKYLATING AGENTS
  • Sponsor:Geron Corp.

Neuromyelitis optica spectrum disorder

Not recruiting

Study on the Effectiveness and Safety of Ravulizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Fingolimod and Interferon Beta-1a in Children with Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Fingolimod
  • Sponsor:Novartis Pharma AG

Idiopathic pulmonary fibrosis

Not recruiting

Study on Axatilimab for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Anti-neutrophil cytoplasmic antibody positive vasculitis+1

Not recruiting

Study on Continuing or Stopping Immunosuppressive Therapy with Rituximab in Patients with ANCA Vasculitis and End-stage Kidney Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Centre Hospitalier Departemental Vendee

Short stature

Not recruiting

Study on the Effects of Somapacitan and Somatropin in Children with Short Stature Born Small for Gestational Age Without Catch-Up Growth by Age 2

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Le Kremlin-Bicetre

What the registry says about research in the country

01 Gastroenterology Research

Innovative studies exploring treatments for inflammatory bowel diseases, with multiple trials investigating fecal microbiota transplantation as a therapeutic approach for Crohn's disease and ulcerative colitis. Research focuses on maintaining remission and improving patient outcomes.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Microbiota-Based Therapies
02 Neurology Studies

Clinical research targeting neurological conditions, including trials for Myasthenia Gravis and innovative treatments for aneurysmal subarachnoid hemorrhage. Studies aim to improve daily living activities and patient outcomes.

  • Myasthenia Gravis Treatment
  • Subarachnoid Hemorrhage Management
  • Neurological Disorders
03 Immunology & Rheumatology

Comprehensive research into autoimmune conditions, including studies on rheumatoid arthritis and Sjögren's syndrome. Trials evaluate novel therapeutic approaches and maintenance treatments for improved disease management.

  • Rheumatoid Arthritis Therapies
  • Sjögren's Syndrome Research
  • Immune System Disorders
04 Pulmonary Medicine

Advanced research in respiratory conditions, including studies on pulmonary hypertension, severe asthma, and interstitial lung disease. Trials focus on evaluating new treatments and improving patient care strategies.

  • Pulmonary Hypertension
  • Severe Asthma Management
  • Lung Fibrosis Treatment
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.